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BACKGROUND: Despite the high prevalence rates of
HIV infection in the African-American community,
African Americans remain underrepresented in HIV
treatment trials.
OBJECTIVE: (1) To develop a questionnaire that mea-
sures attitudes and concerns about HIV treatment
trials among HIV-infected African Americans at a
university-based clinic. (2) To determine actual partic-
ipation rates and willingness to participate in future
HIV treatment trials among HIV-infected African Amer-
icans at a university-based clinic.
DESIGN: Questionnaire development and cross-sec-
tional survey.
SETTING, PARTICIPANTS, AND MEASUREMENTS: In
a sample of 200 HIV-infected African-American adults
receiving medical care at the Pittsburgh AIDS Center for
Treatment (a university-based ambulatory clinic), we
assessed research participation rates and willingness to
participate in future HIV treatment trials, trust in the
medical profession, sociodemographic characteristics,
attitudes, and concerns about HIV treatment trials.
MAIN OUTCOME MEASURES: Research participation
rates and willingness to participate in future HIV
treatment trials.
RESULTS: Only 57% of survey respondents had ever
been asked to participate in an HIV treatment trial but
86% of those asked said yes. Prior research participation
was significantly related to willingness to participate in
future HIV treatment trials (P=.001). Contrary to previ-
ous studies, neither trust/distrust in the medical pro-
fession nor beliefs about the dishonesty of researchers
was associated with research participation rates or
willingness to participate in future HIV treatment trials.
CONCLUSIONS: Having never been asked to participate
in research is a major barrier to the participation of
HIV-infected African Americans in HIV treatment trials.
African Americans who seek medical care for HIV
infection should be asked to participate in HIV treat-
ment trials.
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INTRODUCTION
In the United States, the HIV epidemic disproportionately
affects the African-American population. In 2004, African
Americans accounted for 49% of the estimated 42,524 AIDS
cases diagnosed; this rate was 10 times that for whites.
1
Despite these disproportionate numbers, African Americans
remain underrepresented in HIV treatment trials.
2–5 In a 1995
study, among 4,604 HIV-infected individuals, African Amer-
icans were significantly less likely to be in trials than all other
races or ethnicities.
6 As of October 1999, African Americans
accounted for only 23% of the adults enrolled in HIV treatment
trials.
7 Recent data from the HIV Cost and Services Utilization
Study confirmed that HIV-infected African Americans are less
likely to have access to experimental treatment or to partici-
pate in research than whites.
3
Numerous studies exploring the barriers to African Amer-
icans’ participation in medical research concluded that com-
pared to whites, African Americans are more distrustful of
researchers and less willing to participate in research.
8–10
However, a study comparing African Americans who partici-
pate in research with those who do not showed that research
participants had more positive perceptions of clinical re-
search.
11 We believe that within-culture comparisons are
critical for developing effective mechanisms to increase the
recruitment and retention of African Americans in research.
Therefore, we developed a survey to compare the attitudes and
characteristics of HIV-infected African Americans who have
and have not participated in HIV trials. Given that previous
studies document African Americans’ distrust of research, we
were particularly interested in whether research distrust
influences participation rates in HIV trials.
METHODS
Questionnaire Development
Before constructing the questionnaire, we reviewed existing
instruments used in past research and searched the following
terms in the MEDLINE database: African-American human
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17subjects, attitudes towards research, (HIV) clinical trials, Afri-
can Americans distrust of research, research participants
survey instrument, and research participants questionnaire.
We found no psychometrically validated surveys that assess
research participants’ trust of physician-researchers or their
attitudes about HIV trials. However, previous studies identified
the following variables that influenced the participation of
African Americans and other minority groups in research:
knowledge of research,
5,10 African American (dis)trust of
researchers and the medical community,
7–10 economic group
membership,
7 altruism,
7 religiosity,
7 knowledge of informed
consent,
10 low socioeconomic status,
12 speaking a primary
language other than English,
12 personal inconvenience,
12 and
fear of medical procedures.
12 We incorporated these variables
into our questionnaire, often using the same language found in
previous studies’ instruments. One of the authors (GS), a
psychometrician, reworded some questions and rating scales
to increase consistency across the questions from the multiple
sources and reduce ambiguity where it existed. We included
questions about sociodemographic characteristics, insurance
status, social support networks, drug and alcohol use, prior
research participation, and willingness to participate in future
HIV trials.
To measure trust, we included The Trust in the Medical
Profession (TIMP) scale, an 11-item scale with a single factor
structure, good internal consistency, and good response
variability (Cronbach alpha=.89).
13 The scale uses a 5-point
Likert response of “strongly agree” to “strongly disagree” and
the responses are averaged to form a composite score that
ranges from 1 to 5.
12
To measure religiousness, we included items from the
Multidimensional Measurement of Religiousness/Spirituality
for Use in Health Research.
14 The final questionnaire was a
one-time only, self-administered, anonymous questionnaire
with items from content areas that were of importance in
previous research. Except for the TIMP, the intent was not to
use or develop composite measures in specific content area but
to look at ratings of specific items extracted from other scales.
After developing a draft of the questionnaire, we asked
content experts if it accurately represented the concepts and
the full breadth of information we were trying to assess. We
asked members of the Community Research Advisory Board, a
group housed within the Center for Minority Health at the
University of Pittsburgh Graduate School of Public Health, to
review the questionnaire. We revised the questionnaire in
response to their suggestions.
To further ensure that the questionnaire covered topics
relevant to the target population, we conducted a focus
group consisting of 12 HIV-infected African-American patient
volunteers from the Pittsburgh AIDS Center for Treatment
(PACT). The focus group was 40% female, all were aged 25–
44, and a third had participated in HIV trials. Focus group
participants were asked to review and critique the contents
of the revised questionnaire. Based on their recommenda-
tions, we clarified and reworded ambiguous questions and
response options, and revised the visual format of the
questionnaire. Finally, we asked 5 PACT patient volunteers
to complete the 56-item questionnaire to ascertain the time
needed to complete it. The time varied from 20 to 45 min-
utes; this variation was attributed to varying education
levels and reading ability. A copy of the final questionnaire
is included in the Appendix.
Methods
Overview. We invited all HIV-infected African-American adults
receiving medical care at the PACT to complete the newly
developed questionnaire. The University of Pittsburgh
Institutional Review Board (IRB) approved this study. Because
the survey instrument was an anonymous questionnaire, the
IRB waived a written informed consent document.
Setting, Participants, and Survey Administration. The University
of Pittsburgh Medical Center (UPMC) houses the PACT, a
facility that provides comprehensive medical care to HIV-
infected patients from diverse racial and socioeconomic
backgrounds, regardless of their medical insurance status.
UPMC also houses the NIH-funded Pittsburgh AIDS Clinical
Trials Unit (ACTU), which conducts clinical trials of
antiretroviral therapies and vaccines. Individuals registered
at PACT are recruited into ongoing trials at the ACTU.
In December 2002, 897 patients were registered at PACT;
679 (76%) were men, 597 (66%) were white, and 286 (32%)
were African-American. This is comparable to HIV prevalence
rates among African Americans in Southwestern Pennsylvania
(36%),
15 but lower than prevalence rates in Pennsylvania (51%)
and nationally (40%).
16 All African-American patients at PACT,
aged 18 years or older, were eligible for our study. The only
exclusion criterion was clinical history of cognitive dysfunction
as reported by the medical assistant.
Beginning in July 2003, every African-American patient
presenting for a scheduled clinic visit was invited to participate
in the study by the medical assistant. Patients who expressed
interest were then approached by the Principal Investigator,
screened for eligibility criteria, presented with the study
introductory script, and asked to complete the study ques-
tionnaire. For five participants who had problems reading the
questionnaire, the Principal Investigator read each question
and the participant independently filled in the appropriate
option on a separate questionnaire. Each participant was given
a $10 gift certificate after completing the questionnaire.
Data Analysis. We obtained descriptive statistics for (1)
respondents who had ever been asked to participate in HIV
trials, (2) those who agreed to participate, (3) those who
enrolled, and (4) those who completed a trial. In addition, we
obtained frequency distributions for the responses to the
question about willingness to participate in future HIV trials.
Using chi-square tests and multivariable logistic regression,
we compared independent variables among the following
groups: (1) those who were never asked to participate in HIV
trials versus those who were asked; (2) those who agreed to
participate versus those who refused; (3) those who agreed to
participate and enrolled in a study versus those who agreed
but never enrolled in a study; and (4) those who enrolled and
completed a study versus those who enrolled but did not
complete a study. Any independent variable with a P value of
≤0.15 was included in the multivariable analysis. Using
backward, stepwise, logistic regression, we arrived at a
predictor model for each comparison group with variables
showing statistical significance at P<.05. We also compared
independent variables among those who expressed willingness,
uncertainty, and unwillingness to participate in future HIV
trials.
18 Garber et al.: African Americans and Research Participation JGIMStata 7.0. (Stata Corporation, College Station, Tex) was used
for all analyses. A P value of ≤0.05 was considered statistically
significant.
RESULTS
All 228 (80% of all possible black clinic patients) HIV-infected
black (African, African-American, and Caribbean-American)
patients who presented to PACT from July to November 2003
were invited to join the study. Of those patients, 203 (89%) who
were African Americans were recruited, 2 were ineligible
because of dementia, and 1 declined. Of the 200 respondents,
3 failed to complete the TIMP scale; 197 respondents were
included in all of the analyses. Subanalyses of the group of
patients who required assistance with completing the survey
was not done because of the relatively small number of
patients
5 in this group.
Figure 1 provides a breakdown of the subject flow and
research participation rates among the respondents, illustrat-
ing the four comparison groups. Of 197 survey respondents,
only 114 (57%) had ever been asked to participate in an HIV
trial, 98 (86%) agreed. Eighty (82%) of those who agreed
enrolled, 69 (86%) of whom completed a trial.
Table 1 shows the sociodemographic characteristics of the
respondents. Fifty-six percent were in the 25–44 age category,
78% had known about their HIV infection for >2 years, and
61% had been registered at PACT for >2 years. The mean TIMP
score was 3.44 (halfway between undecided and agree, or
slightly positive trust). The observed coefficient alpha on the
TIMP for our subjects was 0.73 (95% confidence interval [CI]
0.67–0.78).
In the regression analyses, after controlling for being
registered at PACT for >2 years, those asked to participate in
a trial were significantly more likely to be employed and less
likely to be negative about research participation; those who
enrolled were significantly more likely to receive social support
from their spiritual leader and less likely to use marijuana.
Table 2 lists unadjusted odds ratios (OR) from the bivariate
analyses and adjusted OR from the multivariable analyses;
only statistically significant variables from the bivariate ana-
lyses are reported.
Trust in the medical profession did not play a significant
role; there were no statistically significant differences in levels
of trust in any of the four analyses.
Finally, we asked survey respondents about their willing-
ness to participate in future HIV trials. Eighty-three percent
Figure 1. Breakdown of the subject flow and research participation
rates.
Table 1. Sociodemographic Characteristics of 197 HIV-Infected
African-American Participants
Characteristics Percentage
Gender
Male 56
Age (y)
<25 5
25–44 56
45–64 36
≥65 3
Insurance status*
Medicaid 44
Medicare 22
Private 23
None 15
Education
Some high school 12
High school graduate 25
Trade school, college,
or higher
63
Income
<$10,000 33
$10,000–$19,999 16
$20,000–$29,999 6
$30,000–$39,999 4
≥$40,000 3
Unknown 38
Time aware of HIV infection
<1 y 7
1–2y 1 0
>2 y 78
Unknown 5
Time registered at the clinic
<1 y 20
1–2y 1 9
>2 y 61
AIDS classification based on CD4 count
CD4<200 cells/μL2 1
CD4≥200 cells/μL4 5
Unknown 34
*Some patients had more than one type of insurance coverage.
19 Garber et al.: African Americans and Research Participation JGIMTable 2. Significant Predictors of Being Asked, Agreeing, Enrolling,
and Completing HIV Treatment Trials
Unadjusted Adjusted
Odds
ratio
95%
confidence
interval
Odds
ratio
95%
confidence
interval
ASKED: Compared with patients who were never asked to participate in
an HIV treatment trial (n=84), patients who were asked to participate
(n=113)*
More likely to have
known of their
HIV infection for
more than 2 y
2.9 1.3–6.4
More likely to have
been a patient
registered at the
clinic for more
than 2 y
3.5 1.9–6.3 3.1 1.4–7.0
More likely to have
acquired at least
a trade school
education or
some college
education
1.9 1.3–2.9
More likely to be
engaged in some
form of
employment
2.9 1.6–5.3 3.2 1.1–9.3
More likely to have
private insurance
2.2 1.1–4.5
Less likely to be
negative about
research
participation
0.4 0.2–0.8 0.3 0.1–0.7
Less likely to believe
that research
participants must
remain in a study
until the protocol
is completed
0.4 0.2–0.9
AGREEING: Compared with patients who agreed to participate (n=97),
patients who refused to participate in an HIV treatment trial (n=16)
†
Less likely to believe
that research
doctors are
required to
disclose risks to
research
participants
0.2 0.6–0.9
Less likely to believe
that research
participants can
leave a study at
any time during
the protocol
0.2 0.1–1.0 0.1 0.0–0.6
Less likely to
acknowledge
support from God
or a higher power
in dealing with
their disease
0.2 0.1–1.0
(continued on next page)
Table 2. (continued)
Unadjusted Adjusted
Odds
ratio
95%
confidence
interval
Odds
ratio
95%
confidence
interval
Less likely to be
married or in a
committed
relationship
0.1 0.0–0.7
Less likely to have
tried to cut down
on alcohol use at
some point in
their life
0.2 0.1–0.9 0.1 0.0–0.6
ENROLLING: Compared with patients who agreed to participate but did
not enroll in an HIV treatment trial (n=18), patients who agreed and
enrolled (n=79)
‡
More likely to have
been a patient
registered at the
clinic for more
than 2 y
5.4 1.9–15.3 6.7 2.0–22.4
More likely to receive
support in dealing
with their HIV
disease from their
minister or
spiritual leader
5.0 1.5–16.5 4.0 1.1–14.8
More likely to
receive support in
dealing with their
HIV disease from
their HIV physician
4.0 1.1–15.0
More likely to
receive support
in dealing with
their HIV disease
from their friends
3.4 1.1–10.4
Less likely to
question whether
God exists
0.4 0.1–1.1
Less likely to
interpret life
events without
relying on God
0.2 0.1–0.6
Less likely to use
marijuana
0.3 0.1–0.8 0.3 0.1–0.9
More likely to
believe research
doctors are
required to
identify HIV
treatment trials as
a form of research
9.0 1.5–54.2
More likely to believe
that research
doctors are
required to disclose
risks to research
participants
3.7 0.9–15.1
(continued on next page)
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in future trials. Among all respondents, 67% were willing to
participate in future trials, whereas 23% were uncertain and
10% were unwilling. The reasons for willingness to partici-
pate in future trials were to help find a cure for AIDS (86%),
to help the HIV community (65%) and to obtain new and
effective experimental HIV medication(47%). Reasons for
unwillingness and uncertainty about participation were fear
of adverse effects of medications (45%), concern about the
general risks of research (24%), and time constraints (21%).
We assigned those uncertain about future participation to
the unwilling group; in multivariable analysis the only
significant factor related to willingness to participate in future
research was prior research participation (adjusted OR=.6;
95% CI 1.9–11). There was no statistically significant differ-
ence in levels of trust in the medical profession between those
willing, unsure, and unwilling to participate in future HIV
trials. (F2,194=1.15, P=.3) Only 13% of those unwilling or
uncertain were concerned about the honesty of researchers.
DISCUSSION
Multiple studies document African Americans’ low participa-
tion rates in HIV trials.
3–6 However, when we surveyed HIV-
infected African-American patients receiving medical care at
PACT (a university-based clinic), we found that only 57% had
ever been asked to participate in an HIV trial. In fact, when
asked, African Americans seemed very willing to participate in
a trial. Thus, having never been asked was the major barrier to
participation. Contrary to findings in previous studies, we
found that neither distrust in the medical profession nor
beliefs about dishonesty of researchers was significantly
associated with actual participation rates or willingness to
participate in future HIV trials.
These findings are consistent with recent publications that
African Americans are willing to participate in research: A
national study of veterans attending outpatient facilities
reported no race differences in self-reported research partici-
pation.
17 Wendler et al.
18 performed a systematic review of 20
health research studies that reported consent rates by race or
ethnicity. They also found that when invited, African Amer-
icans were not less likely and occasionally were more likely to
consent to research participation compared to non-Hispanic
whites.
Although the bivariate analyses show that both having been
diagnosed with HIV infection for >2 years and being a patient
at PACT for >2 years were significantly associated with being
asked to participate in a trial, the multivariable analyses
revealed that having been a patient at PACT for >2 years was
the significant determinant. After adjusting for being regis-
tered at PACT for >2 years, patients asked to participate in
trials were less likely to be negative about research and less
likely to believe that research participants must remain in a
study until the protocol is completed. This suggests that public
education about research may improve participation rates.
We postulate several reasons for the finding that only 57% of
respondents had ever been asked to participate in an HIV trial.
First, physicians and researchers may have preconceived
notions that African Americans are likely to refuse to partici-
pate in research. Assuming that African Americans are not
interested in research, clinicians may not raise the issue. A
similar dynamic was found in studies of organ donation where
health care providers perceiving black families were less willing
to donate, were requested for organ donation less frequently.
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While organ donation and research participation are different
topics with different emotional impact, it is consistent with the
broader communication theory that suggests that a speaker’s
preconceptions influence interactions. For example, white
researchers may be uneasy talking to African Americans about
research assuming (incorrectly) that patients will react with
anger or distrust given past abuses. The relationship between
the health care practitioner’s ethnicity and whether patients
were asked to participate in trials could not be assessed in this
study because all of the practitioners at PACT are white.
Further research into investigators’ ethnicity, beliefs, and
attitudes is needed. Second, medical researchers simply may
not know how to effectively communicate with African Amer-
icans about research participation particularly in light of the
history of research abuses on the African-American popula-
tion. Third, researchers may believe that African Americans
may not be reliable research participants and thus may be
reluctant to enroll them in research. For example, Shavers-
Hornaday et al.
20 report that researchers believe that it is more
difficult to obtain African-American patients’ compliance and
that African Americans have higher attrition rates. Fourth,
Table 2. (continued)
Unadjusted Adjusted
Odds
ratio
95%
confidence
interval
Odds
ratio
95%
confidence
interval
COMPLETING: Compared with patients who enrolled and completed
the trial (n=68)
§, patients who enrolled but did not complete an HIV
treatment trial (n=11)
Less likely to believe
that HIV medical
research tests
whether new
medications will
benefit patients
0.2 0.0–0.8 0.2 0.0–0.8
Less likely to believe
that the government
has rules to ensure
that medical
research is done
properly
0.3 0.1–1.2
APv a l u eo f≤.05 was considered statistically significant in the
multivariable analysis.
The main reasons for participating were to help find a cure for AIDS (cited
by 77%), to help the HIV community (53%), to get a new and effective
experimental drug (47%), and to help the black HIV community (46%).
Only 16% of the group reported financial compensation as a motivation
for research participation.
*Independent variables with a P value of ≤.15 in the univariate analysis
were included in the multivariable analysis.
†In the group of 16 patients who refused to participate, the 2 most
common reasons for refusal were time constraints (cited by 36% of
patients) and fear of adverse effects of medications (cited by 29%).
‡In the group of 18 patients who agreed to participate but did not enroll,
the most common reason for failure to enroll was time constraints (cited
by 56%).
§In the group of 68 patients who completed an HIV treatment trial, 55
(81%) said they "felt good" about contributing to research.
21 Garber et al.: African Americans and Research Participation JGIMsome researchers believe that they are more likely to encounter
difficulties in contacting patients from minority populations or
in financing effective recruitment efforts that target these
populations.
20–22 Fifth, it is also possible that some patients
were not asked to participate simply because they were
ineligible for ongoing trials. Ineligibility may be because of lack
of requisite clinical diagnoses and ongoing risky behaviors.
However, given that the general policy at PACT is to ask all
patients if they are interested in research and then to
determine eligibility, this is less likely to be a reason.
Several reasons might explain our finding that 86% of
African Americans asked to participate in HIV trials agreed to
do so. First, it may be attributable to the unique clinical setting
in which the survey was done. PACT is a university-affiliated
clinic that provides comprehensive clinical and social services.
Second, PACTemploys an African-American peer advocate who
addresses patients’ concerns and complaints. Third, PACT
employs a resident research coordinator who acts as a liaison
between the clinic and the ACTU; familiar-face coordinators,
who ask patients about research participation in an environ-
ment that caters to their medical and social needs, might
positively influence research participation rates. A study of
HIV-infected patients beginning HIV primary care at Boston
City Hospital reported that when a research associate provided
patients with information about the purpose, role, and avail-
ability of HIV clinical trials, and addressed their concerns
about these trials, the overall rates of participation improved
and there was no longer a significant difference between the
rates of participation by whites and by people of color.
23
Our study found that trust/distrust in the medical profes-
sion was not associated with research participation rates and
willingness to participate in future trials. This is contrary to
reports by Sengupta et al.
7 that African Americans’ distrust
about research institutions was the strongest inverse predictor
of willingness to participate in AIDS clinical trials. The reasons
for our distinctive findings are not clear. It may be that HIV-
infected African Americans who seek medical care at a
university-based clinic are less distrustful of the medical
profession. Ninety percent of survey respondents indicated
that their PACT physician provides considerable support in
coping with their disease. El–Sadr and Capps
4 have noted that
African Americans’ fear of exploitation in research and their
distrust of researchers can be overcome if trust develops
between the primary care provider and the patient. Similarly,
Kass et al.
24 found in a survey of 1,900 research participants
that the patients’ trust in their physicians was instrumental in
the participants’ decision to enroll in a research study.
The major limitation of this study is that of selection bias.
Because the study population is limited to African Americans
at a single university-based clinic, the findings may not be
generalizable to other clinical settings. Although the distinc-
tiveness of some of our findings may also be due in part to the
desire of survey participants to provide socially desirable
responses to questions, we believe this effect is minimal in
our study, not only because the questionnaire was anonymous
but also because participants reported considerable amounts
of alcohol and substance abuse. There is evidence to suggest
that when individuals self-report extensive drug use, the
information provided is likely to be valid.
25
Future studies are needed to assess the beliefs of African
Americans in other clinical settings. These studies should
assess whether there is a relationship between the clinical
services received, satisfaction with these services, and willing-
ness to participate in research. Studies should also assess the
relationship between how African Americans are asked about
research and their willingness to participate in research.
CONCLUSION
This study demonstrates that HIV-infected African Ameri-
cans seeking medical care at a university-based clinic are
likely to participate in HIV trials if asked. This study
suggests that HIV-infected African Americans who seek
medical care for their HIV infection should be asked to
participate in HIV trials.
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